Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurelien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, Francois Xavier Danlos

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    1 Citation (Scopus)

    Résumé

    Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an antibody-cytokine fusion protein, combines interleukin-2 (IL-2) with an anti-IL-2 monoclonal antibody, aiming to stimulate the expansion of CD8 T and natural killer lymphocytes while restricting regulatory T lymphocytes. In the recent publication of the phase 1 dose escalation study of ANV419, a notable gap exists in detailed information regarding patients' prior antitumoral treatments, specifically programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) targeted monoclonal antibodies. Some patients likely retained residual anti-PD-1/PD-L1 monoclonal antibodies, potentially influencing the outcomes of ANV419. In a separate clinical cohort, we retrospectively measured the residual concentration of nivolumab and pembrolizumab, revealing persistent serum concentrations of anti-PD-1/PD-L1 antibodies even months after treatment cessation. This underscores the importance of comprehensively documenting prior immunotherapy details in clinical trials. Such information is crucial for understanding potential interactions that may impact both immunological and clinical effects.

    langue originaleAnglais
    Numéro d'articlee008847
    journalJournal for ImmunoTherapy of Cancer
    Volume12
    Numéro de publication5
    Les DOIs
    étatPublié - 3 mai 2024

    Contient cette citation